Literature DB >> 21865192

Current diagnosis and management of peripheral tuberculous lymphadenitis.

Jose-Mario Fontanilla1, Arti Barnes, C Fordham von Reyn.   

Abstract

Peripheral tuberculous lymphadenitis accounts for ~10% of tuberculosis cases in the United States. Epidemiologic characteristics include a 1.4:1 female-to-male ratio, a peak age range of 30-40 years, and dominant foreign birth, especially East Asian. Patients present with a 1-2 month history of painless swelling of a single group of cervical lymph nodes. Definitive diagnosis is by culture or nucleic amplification of Mycobacterium tuberculosis; demonstration of acid fast bacilli and granulomatous inflammation may be helpful. Excisional biopsy has the highest sensitivity at 80%, but fine-needle aspiration is less invasive and may be useful, especially in immunocompromised hosts and in resource-limited settings. Antimycobacterial therapy remains the cornerstone of treatment, but response is slower than with pulmonary tuberculosis; persistent pain and swelling are common, and paradoxical upgrading reactions may occur in 20% of patients. The role of steroids is controversial. Initial excisional biopsy deserves consideration for both optimal diagnosis and management of the otherwise slow response to therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21865192     DOI: 10.1093/cid/cir454

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  67 in total

1.  Scrofula, the king's evil.

Authors:  Guillaume Moulis; Guillaume Martin-Blondel
Journal:  CMAJ       Date:  2012-02-27       Impact factor: 8.262

Review 2.  Medical management of drug-sensitive active thoracic tuberculosis: the work-up, radiographic findings and treatment.

Authors:  Jared Eddy; Taimur Khan; Frank Schembri
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

3.  Diagnostic accuracy of fine needle aspiration cytology in providing a diagnosis of cervical lymphadenopathy among HIV-infected patients.

Authors:  David Muyanja; Robert Kalyesubula; Elizabeth Namukwaya; Emmanuel Othieno; Harriet Mayanja-Kizza
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

Review 4.  Diagnosis and management of pediatric tuberculosis in Canada.

Authors:  Ian Kitai; Shaun K Morris; Faisal Kordy; Ray Lam
Journal:  CMAJ       Date:  2017-01-09       Impact factor: 8.262

5.  Peripheral Tuberculous Lymphadenitis Masquerading as Metastatic Gastric Carcinoma on F-18 FDG Dual Time Point PET/CT.

Authors:  Su Kon Kim; Jeong Eun Shin; Jai Hyuen Lee
Journal:  Nucl Med Mol Imaging       Date:  2012-09-08

6.  A case of cervical radiculopathy due to tuberculosis cervical lymphadenitis.

Authors:  Jacob Pellinen; Alexandra Lloyd-Smith; Samantha Su; Perrin Pleninger
Journal:  Neurol Clin Pract       Date:  2017-10

7.  Reduced systemic and mycobacterial antigen-stimulated concentrations of IL-1β and IL-18 in tuberculous lymphadenitis.

Authors:  Gokul Raj Kathamuthu; Kadar Moideen; Dhanaraj Bhaskaran; Gomathi Sekar; Rathinam Sridhar; Bharathi Vidyajayanthi; Ganeshan Gajendraraj; Subash Babu
Journal:  Cytokine       Date:  2016-10-26       Impact factor: 3.861

8.  Extrapulmonary tuberculosis: an unusual presentation in an immunocompetent patient.

Authors:  Rosa Lombardi; Serena Pelusi; Lorena Airaghi; Silvia Fargion
Journal:  BMJ Case Rep       Date:  2015-05-06

9.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

Review 10.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.